Anzeige
Meldung des Tages: GOLD-AUSBRUCH: Von der PEA zum Milliarden-Potenzial

Roche Holding Aktie News

Aktie
WKN:  851311 ISIN:  CH0012032113 US-Symbol:  RHHBF Branche:  Pharmazeutika Land:  Schweiz
356,40 CHF
+0,4 CHF
+0,11%
386,03 € 23.01.26
Depot/Watchlist
Marktkapitalisierung *
250,27 Mrd. €
Streubesitz
17,13%
KGV
25,93
Dividende
9,70 CHF
Dividendenrendite
2,72%
neu: Nachhaltigkeits-Score
48 %
Index-Zuordnung
-

Roche Holding News

23.10.25 - GlobeNewswire
[Ad-hoc-Mitteilung gemäss Art. 53] Roche setzt starkes Wachstum in den ersten neun Monaten 2025 fort: Verkäufe steigen um 7% (CER) – Gewinn­prognose für das Gesamtjahr erhöht
Basel, 23. Oktober 2025
20.10.25 - GlobeNewswire
Roche’s Tecentriq showed significant overall and disease-free survival benefits in bladder cancer with ctDNA-guided treatment
Tecentriq reduced the risk of death by 41% and the risk of disease recurrence or death by 36% compared with placebo 1 IMvigor011 is the first global phase III study to read out ...
20.10.25 - GlobeNewswire
FDA approves Roche’s Gazyva/Gazyvaro for the treatment of lupus nephritis
FDA approval based on superiority of Gazyva/Gazyvaro over standard therapy alone, as shown in phase II NOBILITY and phase III REGENCY data 1,2 Gazyva/Gazyvaro is the only ...
18.10.25 - GlobeNewswire
Roche’s phase III evERA data showed giredestrant significantly improved progression-free survival in people with ER-positive advanced breast cancer
Giredestrant plus everolimus reduced the risk of disease progression or death by 44% and 62% in ITT and ESR1 -mutated populations, respectively, in a post-CDK inhibitor setting, ...
17.10.25 - GlobeNewswire
Roche presents new phase III pivotal data for vamikibart in uveitic macular edema (UME), a serious cause of vision loss
Vamikibart is the first non-​steroid targeted therapy designed to address inflammation driving UME and may offer a potential new treatment option for patients Vision improvements ...
17.10.25 - GlobeNewswire
CHMP recommends EU approval of Roche’s Gazyva/Gazyvaro for lupus nephritis
Positive recommendation based on phase II NOBILITY and phase III REGENCY data showing Gazyva/Gazyvaro’s superiority over standard therapy alone 1,2 Gazyva/Gazyvaro is the ...
16.10.25 - GlobeNewswire
Roche presents major advances for its sequencing by expansion technology(1), including a new GUINNESS WORLD RECORD™, at the ASHG conference 2025
Significant progress in bulk RNA sequencing, methylation mapping, multiomics integration, and spatial analyses unlocks research previously out of reach for traditional short read ...
13.10.25 - GlobeNewswire
Roche data at ESMO 2025 showcase advances in science and cancer care across multiple tumour types
Basel, 13 October 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it will present more than 30 abstracts across more than 10 cancer types at the European ...
06.10.25 - GlobeNewswire
Roche receives CE Mark for AI-based Kidney Klinrisk Algorithm(1) and launches new comprehensive chronic kidney disease (CKD) algorithm panel
Roche, in collaboration with KlinRisk, Inc, has received CE-mark for the first AI-based risk stratification tool for assessment of progressive decline in kidney function. This tool will be ...
03.10.25 - GlobeNewswire
FDA approves Roche’s Tecentriq plus lurbinectedin as first-line maintenance therapy for extensive-stage small cell lung cancer
Combination reduced the risk of disease progression or death by 46% and risk of death by 27% in pivotal phase III IMforte study 1 First and only combination therapy for the first-​line ...
03.10.25 - GlobeNewswire
Change in the Roche Board of Directors
Basel, 3 October 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that Dr. Claudia Süssmuth Dyckerhoff has decided not to stand for re-​election as a member of the ...
01.10.25 - GlobeNewswire
Roche commences tender offer for all shares of 89bio, Inc. for $14.50 per share in cash, plus a non-tradeable contingent value right for up to $6.00 per share in cash
Basel, 1 October 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has commenced a tender offer for all of the outstanding shares of common stock of 89bio, ...
30.09.25 - GlobeNewswire
Data show Roche’s sixth-generation Troponin T test offers a new level of accuracy critical for diagnosing heart attacks
Recently granted CE Mark, the novel test delivers improved sensitivity and accuracy for faster and more reliable diagnosis in emergencies. The test helps clinicians quickly identify ...
24.09.25 - GlobeNewswire
Roche presents new data for OCREVUS and fenebrutinib across broad patient populations at ECTRIMS 2025
OCREVUS subcutaneous maintains consistent benefit-​risk profile after two years New late-​breaking data confirms OCREVUS significantly reduces disability progression in adults ...
22.09.25 - GlobeNewswire
Positive phase III results show Roche’s giredestrant significantly improved progression-free survival in ER-positive advanced breast cancer
evERA met its co-​primary endpoints; giredestrant plus everolimus demonstrated significant benefit in ITT and  ESR1 -mutated populations in post-CDK inhibitor setting, compared ...
19.09.25 - GlobeNewswire
CHMP recommends EU approval of Roche’s subcutaneous formulation of Lunsumio for people with relapsed or refractory follicular lymphoma
Lunsumio provides high and long-​lasting response rates, with approximately two-​thirds of patients with a complete response in remission after four years 1 Subcutaneous ...
18.09.25 - GlobeNewswire
Roche enters into a definitive merger agreement to acquire 89bio, and its phase 3 FGF21 analog for the therapy of moderate to severe MASH
89bio’s pegozafermin allows for a potentially best-​in-disease treatment for moderate to severe Metabolic Dysfunction-​Associated Steatohepatitis (MASH), one of the most prevalent ...
05.09.25 - GlobeNewswire
New data for Roche's Vabysmo reinforce its efficacy, safety and durability in neovascular or “wet” age-related macular degeneration (nAMD)
In AVONELLE-​X, the largest long-term extension trial in nAMD, disease control and durability were maintained over 4 years, with nearly 80% of patients on extended dosing by study ...
04.09.25 - GlobeNewswire
Roche receives CE mark for Contivue, its Port Delivery Platform containing Susvimo, for neovascular age-related macular degeneration (nAMD)
Susvimo is under review with the EMA and once approved will be the first continuous delivery treatment for nAMD, affecting 1,7 million in the European Union 1 New seven-​year data ...
30.08.25 - GlobeNewswire
Roche and Alnylam advance zilebesiran into global phase III cardiovascular outcomes trial for people with uncontrolled hypertension
Phase III trial informed by comprehensive KARDIA data set generated through three Phase II studies: KARDIA-1, KARDIA-2 and KARDIA-3 In the Phase II KARDIA-3 study, presented ...

Newssuche

Videos

newspaper
22.01.26 -5,56%
Trading Insights vom 22.01.26
Preisschock bei Erdgas! Was sind die Gründe, wie geht man damit um? Gold auf neuem Allzeithoch: wie ... Mehr »